#WeekendRead
Women experience medication side effects at roughly twice the rate of men.
Guest contributor Jessica Federer asks a consequential question: what happens when healthcare's evidence base doesn't fully reflect the people it serves?
The Long View. Read it here
capsul.news/the-long-view-of…
1
11
#ICYMI
Women account for roughly two-thirds of US GLP-1 users.
Guest contributor Jessica Federer sees a broader lesson: some of healthcare’s most obvious opportunities may still be hiding in plain sight.
The Long View. Read it here
capsul.news/the-long-view-of…
1
12
A healthcare system built on incomplete data leaves lasting blind spots. Guest contributor Jessica Federer explores the implications of a striking fact: women weren't required in US studies until 1993.
Read The Long View here capsul.news/the-long-view-of…
Sign up for Capsul here: capsul.news/join-capsul/
5
Guest contributor Jessica Federer, a globally recognized leader in health technologies and women’s health writes : AI changes how fast we analyze the data we have; sex-based differences change whether we have the right data in the first place.
The Long View. Read it here...
capsul.news/the-long-view-of…
1
29
Sign up for Capsul here: capsul.news/join-capsul/
3
Revolution has created “a cottage industry of competitors,” says CEO Mark Goldsmith. His answer: stay ahead on science. And what does he say about who is watching?
Therapeutic Thursday. Read it here...
capsul.news/therapeutic-thur…
1
12
Sign up for Capsul here: capsul.news/join-capsul/
2
“We’ve decided we will unlock any compelling strategy in first line,” says Revolution’s CEO. RASolute 303 and 304 are evaluating Rasonque in first-line PDAC. What else is in the first-line programs?
Therapeutic Thursday. Read it here...
capsul.news/therapeutic-thur…
1
17
Sign up for Capsul here: capsul.news/join-capsul/
1
Revolution CEO Mark Goldsmith on Rasonque’s early sales: “The uncertainty is actually baked into the data.” Three overlapping patient groups have been treated so far. Which does he expect to be the stable core of demand?
Therapeutic Thursday. Read it here...
capsul.news/therapeutic-thur…
1
8
Sign up for Capsul here: capsul.news/join-capsul/
3
Rasonque booked $197.6m in roughly five weeks to Sept. 30 after its Aug. 26 FDA approval, the best launch-quarter sales for an oncology drug ever. Revolution’s CEO is still tempering expectations. Why?
Therapeutic Thursday. Read it here...
capsul.news/therapeutic-thur…
Sign up for Capsul here: capsul.news/join-capsul/
4
The EU offers three routes for herbal medicines. The US has no herbal-specific route. Birch triterpene gel is the one product taken through both systems. How did it fare?
Watchdog Wednesday. Read it here...
capsul.news/watchdog-wednesd…
1
7





